AbbVie (NYSE:ABBV) Posts Earnings Results, Beats Estimates By $0.04 EPS

AbbVie (NYSE:ABBV) issued its quarterly earnings results on Friday. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04, FiscalAI reports. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.78 billion. During the same period in the prior year, the firm posted $2.97 earnings per share. The business’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie updated its Q3 2026 guidance to 3.840-3.880 EPS.

Here are the key takeaways from AbbVie’s conference call:

• Strong second-quarter execution lifted revenue 10.2% to nearly $17 billion and adjusted EPS to $3.65, beating expectations. AbbVie raised full-year revenue guidance by $300 million to approximately $67.6 billion and increased adjusted EPS guidance to $13.87–$14.07.
• Immunology and neuroscience remained key growth engines, led by SKYRIZI sales of $5.5 billion, up 24%, and RINVOQ sales above $2.5 billion, up 23.7%; neuroscience revenue grew about 20%. Management expects further SKYRIZI momentum from a potential U.S. approval of subcutaneous Crohn’s induction dosing later this year.
• AbbVie highlighted multiple pipeline and business-development catalysts, including the planned Apogee acquisition, European approvals for RINVOQ in vitiligo and alopecia areata, expected U.S. approval decisions for tavapadone, and progress across oncology ADCs and immunology combinations.
• The Apogee transaction is expected to close in the third quarter and will dilute 2026 EPS by an estimated $0.14, while increasing R&D spending and interest expense. AbbVie plans to use interim financing and issue long-term debt, targeting a return to two-times net leverage within two to three years.
• Oncology revenue declined 2.4% operationally, primarily due to expected IMBRUVICA pressure from IRA pricing and competition, while aesthetics revenue fell 0.9% as JUVÉDERM sales declined 6.6%. HUMIRA sales also fell 36.1% because of biosimilar competition.

AbbVie Stock Down 2.4%

Shares of NYSE:ABBV opened at $251.33 on Friday. AbbVie has a 52-week low of $187.62 and a 52-week high of $267.47. The stock has a market cap of $444.05 billion, a price-to-earnings ratio of 123.81, a PEG ratio of 0.85 and a beta of 0.30. The business has a 50-day moving average price of $239.10 and a 200-day moving average price of $224.05.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s dividend payout ratio is currently 340.89%.

Hedge Funds Weigh In On AbbVie

A number of institutional investors have recently bought and sold shares of the business. State Street Corp boosted its holdings in shares of AbbVie by 1.4% in the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after acquiring an additional 1,119,274 shares during the last quarter. Bank of America Corp DE grew its position in AbbVie by 1.4% during the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock worth $5,900,617,000 after purchasing an additional 356,394 shares during the period. Wellington Management Group LLP raised its stake in shares of AbbVie by 41.7% during the 4th quarter. Wellington Management Group LLP now owns 14,926,683 shares of the company’s stock valued at $3,410,598,000 after buying an additional 4,389,782 shares during the last quarter. Amundi lifted its holdings in shares of AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after buying an additional 1,414,621 shares during the period. Finally, Raymond James Financial Inc. raised its position in AbbVie by 2.4% during the third quarter. Raymond James Financial Inc. now owns 9,557,701 shares of the company’s stock valued at $2,212,110,000 after acquiring an additional 220,221 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Solid second-quarter results: AbbVie reported adjusted EPS of $3.65, above the $3.60 consensus estimate, while revenue rose 10.2% year over year to $16.99 billion. Reuters article
• Positive Sentiment: Immunology and neuroscience remained growth drivers: Skyrizi revenue reached $5.505 billion and Rinvoq generated $2.525 billion, while neuroscience revenue increased 20.3% to $3.228 billion. Botox also showed signs of stabilization, supporting the company’s diversified growth profile. AbbVie earnings release
• Positive Sentiment: Pipeline and portfolio expansion: AbbVie is advancing a global Phase 2/3 combination study in acute myeloid leukemia and recently received European approval for Rinvoq in severe alopecia areata, adding potential long-term growth opportunities. AML trial article
• Neutral Sentiment: Near-term guidance was broadly in line: Third-quarter adjusted EPS guidance of $3.84–$3.88 brackets the $3.85 consensus estimate, but revenue guidance of approximately $17.2 billion is slightly below the $17.3 billion analyst forecast.
• Negative Sentiment: Full-year EPS outlook was reduced: AbbVie lowered 2026 adjusted EPS guidance to $13.87–$14.07 from $13.91–$14.11. The revised range includes an estimated $0.14-per-share dilution from the planned $10.9 billion acquisition of Apogee Therapeutics, pushing the midpoint below Wall Street expectations. Zacks guidance article
• Negative Sentiment: Acquisition and execution concerns weigh on sentiment: Investors are balancing Apogee’s potential to strengthen AbbVie’s immunology pipeline against its immediate earnings dilution, while oncology revenue fell 1.5% and aesthetics revenue was essentially flat during the quarter.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Wells Fargo & Company raised their price target on AbbVie from $260.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, July 10th. Canaccord Genuity Group boosted their price target on AbbVie from $273.00 to $282.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Finally, DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $269.29.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.